Overview of 3L+ strategies
Regorafenib, TAS-102 ± bevacizumab
What are currently approved options for all comers who receive 3L+ systemic treatment for mCRC?
The CORRECT study
What was the name of the phase 3 trial of regorafenib?
The order in which different therapies are given to a patient as their disease progresses
What does the term “line of therapy” refer to?
Sotorasib
What is the name of the drug that targets KRAS-G12C?
The SUNLIGHT study
What was the name of the phase 3 trial of TAS-102 ± bevacizumab?
An alternative to the traditional concept of lines of treatment, including chemotherapy switching, maintenance therapy, drug holidays and surgical resection of metastases
What is the continuum of care?
Trastuzumab deruxtecan
What is the name of the
HER2-targeted treatment?
Fatigue, HFS and diarrhoea
What are the three most common adverse events associated with regorafenib?
The need to limit cumulative dose of oxaliplatin cycles and associated neurotoxicity
What was the rationale behind the evolution of maintenance treatment?
3–4%
What is the prevalence of the KRAS‑G12C mutation in mCRC?
Neutropenia, nausea and hypertension
The incidence of which adverse events was higher for patients receiving
TAS-102 + bevacizumab compared with TAS-102 alone?
Following progressive disease while on maintenance therapy
When might an initially successful induction therapy be reintroduced?
2%
What is the prevalence of HER2 amplifications in mCRC?
11.6 vs 10.3 months
What was the mOS in the US sequencing study for Reg–Tri vs
Tri–Reg in 4L?
The de-escalation of treatment intensity to improve QoL and
side-effects without compromising therapeutic efficacy or disease control
What is maintenance therapy?